10-Q: Applied Therapeutics Reports Q3 2024 Results, Provides Update on Clinical Programs

Applied Therapeutics reports a net loss of $68.6 million for Q3 2024, while highlighting progress in its clinical programs and regulatory submissions.

Summary

• Applied Therapeutics reported a net loss of $68.6 million for the third quarter of 2024, compared to a net loss of $42.4 million for the same period in 2023.
• The company's total revenue for the quarter was $0.1 million, primarily from research and development services.
• Research and development expenses increased to $14.8 million in Q3 2024 from $10.8 million in Q3 2023, driven by increased clinical trial costs for AT-007.
• General and administrative expenses also rose significantly to $15.0 million in Q3 2024 from $4.7 million in Q3 2023, due to increased commercialization efforts.
• The company's cash and cash equivalents stood at $98.9 million as of September 30, 2024.
• Applied Therapeutics expects its current cash and cash equivalents, along with projected milestone payments from Advanz Pharma, to fund operations into 2026.
• The company is actively pursuing additional financing options, including equity, debt, and royalty financing.
• The FDA has extended the review period for the New Drug Application (NDA) for govorestat (AT-007) for the treatment of Classic Galactosemia by three months, with a new PDUFA target action date of November 28, 2024.
• The company expects to submit an NDA for govorestat for the treatment of SORD Deficiency early in the first quarter of 2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is progress in clinical programs and regulatory submissions, the significant net loss and the delay in the FDA review are concerning. The company's cash position and pursuit of additional financing provide some reassurance, but the overall sentiment is neutral to slightly negative.

Positives

• The company's cash position of $98.9 million is expected to fund operations into 2026.
• The company is actively pursuing additional financing options.
• The FDA has granted Priority Review status to the NDA for govorestat for Classic Galactosemia.
• The company has aligned with the FDA on the regulatory path forward for govorestat for SORD Deficiency.
• Positive interim 12-month results from the Phase 3 INSPIRE trial for SORD Deficiency were achieved.
• The company has received orphan drug designation and rare pediatric disease designation for AT-007 in PMM2-CDG.

Negatives

• The company reported a significant net loss of $68.6 million for Q3 2024.
• Research and development expenses increased to $14.8 million in Q3 2024.
• General and administrative expenses rose to $15.0 million in Q3 2024.
• The FDA has extended the review period for the NDA for govorestat for Classic Galactosemia by three months.
• The company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing.

Risks

• The company is subject to risks common to companies in the biotechnology industry, including risks of failure of preclinical studies and clinical trials.
• The company is dependent on key personnel, protection of proprietary technology, and compliance with government regulations.
• The company is dependent on third-party manufacturers.
• The company may face substantial competition.
• The company may face risks related to strategic collaborations to develop its product candidates.
• The company's product candidates may fail to achieve market acceptance necessary for commercial success.
• The company may be adversely affected by product liability lawsuits.
• The company's insurance policies may be inadequate and potentially expose it to unrecoverable risks.
• The company is subject to healthcare laws and regulations, which carry substantial penalties for noncompliance.
• Coverage and adequate reimbursement may not be available for the company's product candidates.
• Healthcare reform measures may have a negative impact on the company's business and results of operations.
• The company's ability to use its net operating losses to offset future taxable income may be subject to certain limitations.

Future Outlook

The company expects its current cash and cash equivalents, along with projected milestone payments from Advanz Pharma, to fund operations into 2026. The company also expects to submit an NDA for govorestat for the treatment of SORD Deficiency early in the first quarter of 2025.

Management Comments

• The company continues to evaluate several potential long-term financing options, including equity capital, debt, convertible debt, and synthetic royalty financing.
• The company is in active dialogue with several potential partners regarding business development opportunities related to one or more of its programs.

Industry Context

The company is operating in the competitive biopharmaceutical industry, focusing on rare diseases with high unmet medical needs. The company's approach leverages recent technological advances to design improved drugs and employs early use of biomarkers to confirm biological activity.

Comparison to Industry Standards

• The company's Q3 2024 net loss of $68.6 million is significant for a clinical-stage biopharmaceutical company, reflecting the high costs associated with drug development.
• The increase in research and development expenses to $14.8 million is typical for companies advancing clinical programs, particularly for late-stage trials.
• The rise in general and administrative expenses to $15.0 million indicates the company's preparations for potential commercialization.
• The company's cash position of $98.9 million is relatively strong for a company of its size and stage, providing a runway into 2026.
• Compared to other companies in the rare disease space, Applied Therapeutics is progressing its lead candidate, AT-007, through regulatory submissions, which is a key milestone.
• The company's reliance on third-party manufacturers is a common practice in the industry, but it also introduces risks related to supply chain and quality control.

Related Party Transactions

• During the three and nine months ended September 30, 2024, the Company made payments to Alexandria LaunchLabs of approximately $25,000 and $0.1 million, respectively.

Stakeholder Impact

• Shareholders may be concerned about the company's net loss and the delay in the FDA review.
• Employees may be affected by the company's financial performance and any potential restructuring.
• Patients may benefit from the company's progress in developing treatments for rare diseases.
• Creditors may be concerned about the company's ability to repay its debts.
• Suppliers may be affected by the company's financial performance and any potential changes in its operations.

Next Steps

• The company expects to submit an NDA for govorestat for the treatment of SORD Deficiency early in the first quarter of 2025.
• The company will continue to pursue additional financing options.
• The company will continue to engage with the FDA and EMA regarding regulatory submissions for govorestat.
• The company plans to initiate a clinical development program on AT-007 in PMM2-CDG.

Key Dates

Keywords

Applied Therapeutics, AT-007, govorestat, Galactosemia, SORD Deficiency, clinical trials, FDA, NDA, PDUFA, biopharmaceutical, rare diseases, research and development, financial results, regulatory approval, commercialization